Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies

Abstract

Haematological malignancies are heterogeneous groups of cancers of the bone marrow, blood or lymph nodes, and while therapeutic advances have greatly improved the lifespan and quality of life of those afflicted, many of these cancers remain incurable. The iron-dependent, lipid oxidation-mediated form of cell death, ferroptosis, has emerged as a promising pathway to induce cancer cell death, particularly in those malignancies that are resistant to traditional apoptosis-inducing therapies. Although promising findings have been published in several solid and haematological malignancies, the major drawbacks of ferroptosis-inducing therapies are efficient drug delivery and toxicities to healthy tissue. The development of tumour-targeting and precision medicines, particularly when combined with nanotechnologies, holds potential as a way in which to overcome these obstacles and progress ferroptosis-inducing therapies into the clinic. Here, we review the current state-of-play of ferroptosis in haematological malignancies as well as encouraging discoveries in the field of ferroptosis nanotechnologies. While the research into ferroptosis nanotechnologies in haematological malignancies is limited, its pre-clinical success in solid tumours suggests this is a very feasible therapeutic approach to treat blood cancers such as multiple myeloma, lymphoma and leukaemia.

The Novel Link between Gene Expression Profiles of Adult T-Cell Leukemia/Lymphoma Patients’ Peripheral Blood Lymphocytes and Ferroptosis Susceptibility

“…Furthermore, research into ferroptosis nanotherapeutic technology for hematological malignancies is also progressing, highlighting the potential of ferroptosis induction as a treatment strategy for ATL [17,113]. This study represents the pioneering investigation into the interplay between ATL and pathways associated with ferroptosis.…”

Impact of ferroptosis-related risk genes on macrophage M1/M2 polarization and prognosis in glioblastoma

“…Imatinib is an oral targeted therapy drug known as a tyrosine kinase inhibitor. Cysteine depletion in an imatinib-resistant chronic myeloid leukemia cell line induces ferroptosis (Mynott et al, 2023). However, the relationship between their effects on macrophage polarization and drug sensitivity is unclear, and the specific mechanism and in vivo manifestation need to be confirmed.…”

Maresin1 improves hippocampal neuroinflammation and cognitive function in septic rats by activating the SLC7A11 / GPX4 ferroptosis signaling pathway

“…Ferroptosis, a relatively recently discovered programmed cell death associated with iron dependence [37][38][39] , is a complex pathological event primarily orchestrated by three elements: iron overload, lipid accumulation, and amino acid metabolism 40,41 . Iron overload is a cardinal event of ferroptosis, with traditional ferroptosis activators increasing intracellular iron accumulation by suppressing the antioxidant system.…”